0.949 C 9.4-14.9 11.8467 1.52 C 8.5 -14.9 12.51 1.91 CRA-EDV P 1. 6-11.8 4.4297 2.13 0.200 P 1. Background: Biologic therapies have led to a dramatic change in the management of rheumatologic diseases. Although biologic agents provide profound clinical benefits, various adverse events are associated with their use particularly an increased risk of the reactivation of latent tuberculosis. Therefore, screening for latent tuberculosis infection (LTBI) is imperative before initiating biologic agents 1 . Although tuberculin skin test (TST) is the most common test for detecting LTBI, Bacillus Calmette-Gue'rin (BCG) vaccination and non-tuberculosis Mycobacterium infections, can lead to false positive TST results. Interferon-gamma release assay (IGRA) measures the immune response to tuberculosis specific antigens that do not cross react with BCG, and therefore, do not cause false positive reactions in BCG recipients. Its positiveness indicates the presence of tuberculosis infection either latent or active 2 . Objectives: We aimed to prevent the unnecessary anti-tuberculosis prophylaxis in patients whom biologic therapy is planned by evaluating the concordance between the TST and IGRA. Methods: Patients who have been receiving biologic therapy due to chronic inflammatory arthritis were enrolled in this study. Demographic and clinical data, TST and IGRA results were recorded. The agreement between IGRA and TST results was evaluated by Kappa coefficient. Results: A total of 35 patients were included; 15 (42.8%) were male and mean age was 43.74±12.72 years. Of the 22 TST positive patients, 13 (37.1%) were IGRA negative. Of the 13 TST negative patients, 3 (8.6%) were IGRA positive. Nine (25.7%) patients were positive for either of the two tests and 10 (28.6%) patients were negative for both tests. There was statistically significant discordance between two tests (p:0.021; p<0.05) ( Table 1) . While positive rate of TST was 62.9%, positive rate of IGRA was 34.3% and Kappa consistency coefficient between two tests was 15.4% (p:0.283; p>0.05). Background: Musculoskeletal ultrasound (MSUS) is a useful imaging technique in paediatric rheumatic diseases (PRD). US has several advantages over other imaging techniques: it is non-invasive, radiation free, rapid, highly accepted by the patients and does not require sedation for scanning in younger children. However, MSUS examination is incriminated to be an operator dependent technique. Moreover, the variability of normal sonoanatomy in children, due to ossification, makes the acquisition and interpretation of MSUS images difficult. The variability in background and experience of ultrasonographers in different countries requires an international multidisciplinary effort for an optimal standardization of MSUS performance in PRD. Objectives: To perform a systematic literature review on guidelines for MSUS for children published by international societies and articles on how to perform MSUS scanning in children. This represents the first step for an EULAR taskforce, which objective is to develop EULAR Standardized Procedures for Ultrasound Imaging in Pediatric Rheumatology through a consensus process among rheumatologists, paediatric rheumatologists, and radiologists highly experienced in the performance, teaching and research in paediatric MSUS in rheumatologic disease. Methods: The objective was reformulated according to the PICO-adapted approach, as follows: body parts, ultrasound, and scanning procedures. For each component several synonyms were used. Search limits were applied for animal studies and age. The literature search was performed in Medline and Embase from databases inception to 1st June 2016. References identified were imported into a bibliographic manager and duplicates were removed. To identify eligible studies the remaining articles were assessed by title and abstract. Only articles in English were retained. From the selected studies, data about the examined area, patient position, probe placement, scanning method, landmarks and pathologies using a predefined data collection form. Results: The literature search resulted in 6059 articles, of which 4856 were captured in Medline and 1203 in Embase. Figure 1 shows the the study flow-chart for article selection. After removing duplicates and scanning titles and abstracts, 295 articles remained for detailed review. After full-text review, 107 articles were excluded. The main reason for article exclusion after full-text review was the lack of standardized examination. Of the remaining articles, 2 described shoulder structures, 14 elbow structures, 5 wrist structures, 9 hand structures, 25 hip structures, 41 knee structures, 14 ankle structures and 2 foot structures. The number of structures described for each joint part was as follows: 3 shoulder, 13 elbow, 2 wrist, 4 hand, 7 hip, 25 knee, 14 ankle, 1 foot. Background: The OMERACT Ultrasound scoring system (USSS) of joint in RA has been shown to be reliable and sensitive to change when used in clinical trial setting. However it is unclear whether this reliability is also achieved in clinical daily practice among Rheumatologists performing US in a non-research setting and using different machines. Objectives: To assess agreement between non-research sonographers in scoring synovitis using the OMERACT USSS and using the scoring of an OMERACT expert as gold standard. To assess the reliability of the USSS by using different US machines. Methods: First an OMERACT US expert presented the scoring method and supervised a training session. The wrist, MCP 2 and 3 joints of the left hand (dorsal aspect) of 3 RA patients were then successively evaluated by 9 Rheumatologists with 3 different US machines: Hitachi Arietta = H, GE Logic E9 = G, Esaote MyLab 7= E. The USSS included B-mode acquisition of synovial hypertrophy (SH), joint effusion (JE) and bone erosion (BE), and Power-Doppler (PD) activity. JE, SH and BE were scored binary; SH and PD were score semi quantitatively (0 to 3), by both the 9 participating Rheumatologists and the OMERACT US expert. The agreement between each participant with the scoring of the OMERACT US expert was quantified by proportions. The inter-US machine reproducibility was assessed by kappa statistics for discrete variables and weighted kappa's for ordinate. Results: The 3 joints of 3 patients each were evaluated on the 4 US items (SH, JF, BE, PD) on a different US machine. So 27 values were obtained for each joint within each item. The percentages of exact agreement (PEA) between these 27 values and the scores of the OMERACT US expert were calculated and ranged between 33% (9/27) for SH-MCP3, 37% for JF-MCP2 and PD-Wrist, 41% for SH-wrist, 48% BE-MCP3, 52% PD-MCP3, 56% PD-MCP3, 59 JF-wrist and BE-MCP2, 63% JF-MCP3, 67% SH-MCP2 and 78% (21/27) for BE-wrist. For the inter-US machines reproducibility, kappa between the 3 machines was calculated on 9 data (3 patients x 3 joints). The reliability was low for detecting JE ≤0.211. Acceptable reliability among machines was found for SH, BE and PD (table 1). Conclusions: Non OMERACT-expert Rheumatologists can apply the USSS, and this score works well across different machines. The difference among machines Abstract FRI0651 - Table 1 Inter-observer reliability Intra-observer reliability and sonographers is mostly captured by the low reliability of JE. The OMERACT USSS could be used by sonographers in their everyday clinical practice to evaluate the activity of RA patients. Further studies in clinical-based settings will allow to define more precisely the applicability of this scoring system. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.5435
